Orchestra BioMed Holdings (OBIO) Non Operating Investment Income (2022 - 2026)
Orchestra BioMed Holdings (OBIO) posted quarterly Non Operating Investment Income of -$100000.0 for Q1 2026, down 566.67% year-over-year from $21428.6 in Q1 2025, and down 766.67% quarter-over-quarter from $15000.0 in Q4 2025.
Orchestra BioMed Holdings (OBIO) Non Operating Investment Income (2022 - 2026) Analysis & Trends
Orchestra BioMed Holdings (OBIO) has reported Non Operating Investment Income for 5 consecutive years, with -$100000.0 the latest figure, recorded in Q1 2026.
- In Q1 2026, Non Operating Investment Income fell 566.67% year-over-year to -$100000.0; the TTM figure through Mar 2026 stood at -$77000.0 (down 134.84% YoY), while the FY2025 annual figure was $8000.0, down 87.1% from the prior year.
- Non Operating Investment Income fell to -$100000.0 in Q1 2026 per OBIO's latest filing, from $15000.0 in the prior quarter.
- Across five years, Non Operating Investment Income topped out at $1.7 million in Q2 2022 and bottomed at -$1.2 million in Q4 2022.
- Historically, Non Operating Investment Income has averaged $7058.8 across 5 years, with a median of -$15000.0 in 2024.
- Annual changes were most pronounced in 2024 — Non Operating Investment Income soared 536.84% — and 2025, when it slumped 850.0%.
- Orchestra BioMed Holdings' Non Operating Investment Income stood at -$1.2 million in 2022, then soared by 104.24% to $51000.0 in 2023, then surged by 154.9% to $130000.0 in 2024, then sank by 88.46% to $15000.0 in 2025, then slumped by 766.67% to -$100000.0 in 2026.
- Business Quant data shows OBIO's Non Operating Investment Income at -$100000.0 in Q1 2026, $15000.0 in Q4 2025, and $29000.0 in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Non Operating Investment Income (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | - |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | - |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | - |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | - |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | - |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | - |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | - |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | - |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | - |
| 10 | Orchestra BioMed Holdings | 265.06 Mn | 80.63 Mn | 63,000.00 | -41,000.00 |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | -41,000.00 |
| Jun 30, 2026 | -41,000.00 |
| Mar 31, 2026 | -100,000.00 |
| Mar 31, 2026 | -100,000.00 |
| Dec 31, 2025 | 15,000.00 |
| Dec 31, 2025 | 15,000.00 |
| Sep 30, 2025 | 29,000.00 |
| Sep 30, 2025 | 29,000.00 |
| Jun 30, 2025 | -21,000.00 |
| Jun 30, 2025 | -21,000.00 |
| Mar 31, 2025 | -15,000.00 |
| Mar 31, 2025 | -15,000.00 |
| Dec 31, 2024 | 130,000.00 |
| Dec 31, 2024 | 130,000.00 |
| Sep 30, 2024 | 121,000.00 |
| Sep 30, 2024 | 121,000.00 |
| Jun 30, 2024 | -15,000.00 |
| Jun 30, 2024 | -15,000.00 |
| Mar 31, 2024 | 2,000.00 |
| Mar 31, 2024 | 2,000.00 |